In fact, all patients, including those receiving placebo and both doses of PR‐PFD, showed a slight but significant reduction in ALT and AST serum levels (as well as ALP levels), administered continuously over 24 months, demonstrating anti‐inflammatory properties and a good safety profile in patients with compensated liver cirrhosis. This evidence concerns the gene GPT and cirrhosis of liver.